1 insider has bought $100k of ADMA BIOLOGICS, INC. shares across 1 disclosed dealing since May 2026.
| May 12, 2026 | Grossman Jerrold B — director | $100,125 |
ADMA BIOLOGICS, INC. is classed as health care. By value disclosed, that ranks 30th of the 44 health care companies where insiders bought in the last twelve months.
Companies with a comparable amount of disclosed buying: Annovis Bio, Inc. · Anteris Technologies Global Corp. · Verrica Pharmaceuticals Inc. · DarioHealth Corp. · AUNA S.A. · BlossomHill Therapeutics, Inc.
See also the biggest buys, cluster buying and the most-active companies.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Every row is a public regulatory disclosure — a Form 4 filing with the SEC — collected within minutes of being published. We don’t take company submissions and we don’t edit the numbers; the only thing we add is the rating and the reasoning behind it.
Sometimes. A insider buying with their own money is one of the few honest signals in the market, but plenty of purchases are routine — small top-ups, scheme allocations, or a well-paid executive rounding out a holding. That’s what our six-point check is for: it separates the conviction buys from the housekeeping, and shows you which is which.
The pipeline runs every 15 minutes through the trading day, so a new disclosure appears here shortly after it’s filed. Company stats refresh daily.
Yes — that’s what the app is for. Follow ADMA BIOLOGICS, INC. and you’ll get a push the moment a insider files, with the full analysis attached, plus alerts if the price moves after a buy you’re following.
No. ddbx rates the conviction behind insider buys and shows the reasoning. It’s information, never a recommendation, and never a guarantee. What you do with it is your call.